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Abstract
Background: Plasma concentrations of sFlt-1, the soluble form of the vascular endothelial growth
factor receptor (VEGF), markedly increase during coronary artery bypass graft (CABG) surgery
with extracorporeal circulation (ECC). We investigated if plasma sFlt-1 values might be related to
the occurrence of surgical complications after CABG.
Methods: Plasma samples were collected from the radial artery catheter before vascular
cannulation and after opening the chest, at the end of ECC just before clamp release, after cross
release, after weaning from ECC, at the 6th and 24th post-operative hour. Thirty one patients were
investigated. The presence of cardiovascular, haematological and respiratory dysfunctions was
prospectively assessed. Plasma sFlt-1 levels were measured with commercially ELISA kits.
Results: Among the 31 investigated patients, 15 had uneventful surgery. Patients with and without
complications had similar pre-operative plasma sFlt-1 levels. Lowered plasma sFlt-1 levels were
observed at the end of ECC in patients with haematological (p = 0.001, ANOVA) or cardiovascular
(p = 0.006) impairments, but not with respiratory ones (p = 0.053), as compared to patients with
uneventful surgery.
Conclusion: These results identify an association between specific post-CABG complication and
the lower release of sFlt-1 during ECC. sFlt-1-induced VEGF neutralisation might, thus, be beneficial
to reduce the development of post-operative adverse effects after CABG.
Introduction
Coronary artery bypass graft (CABG) surgery with extra-
corporeal circulation (ECC) is associated with an inflam-
matory response [1,2]. Alterations of lipidic, cytokine,
and colony stimulating factor (CSF) networks observed
during and after CABG surgery might be involved in the
post-CABG multiple organ failure syndrome [3-7]. The
angiogenic network was also affected during and after
CABG [8-10]. Among angiogenic growth factors, vascular
endothelial growth factor (VEGF) fulfils a central role in
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vascular healing in response, for example, to vascular
trauma induced by mechanical disruption [11,12]. In vivo
VEGF induces angiogenesis as well as permeabilisation of
blood vessels and play central role in the regulation of vas-
culogenesis [12]. VEGF acts through two membrane
receptors, Flt-1 (VEGFR-1) and KDR (VEGFR-2) which
belong to the receptor tyrosine kinase superfamily. Solu-
ble forms of Flt-1 (sFlt-1) and KDR (sKDR) are found in
human plasma [12]. Studies highlighted that sFlt-1 is
capable of sequestering VEGF and preventing signal trans-
duction [12]. Moreover, sFlt-1 can act as an endogenous
VEGF inhibitor not only by sequestering VEGF but also by
binding and inactivating membrane-bound Flt-1 and
KDR receptors through a mechanism involving receptor
homodimerisation or heterodimerisation [13]. Recently
we reported the release of sFlt-1 (but not sKDR) during
uneventful CABG surgery and hypothesized that sFlt-1 by
neutralizing VEGF and/or by inactivating membrane-
bound Flt-1 and KDR receptors, might play a role in the
occurrence of post-CABG complications [14]. In order to
test this hypothesis we investigated whether the plasma
levels of sFlt-1 was related to complication after CABG.
Patients and methods
Study population
According to the principles outlined in the Declaration of
Helsinki and in agreement with the ethic committee of
our University Hospital, a total of 31 patients were
included in a study investigating cytokine and lipid medi-
ator blood concentrations during CABG from January
1995 and December 1996. Patients were selected on a
consecutive manner according to the availability of inves-
tigators. Only patients with a preoperative ejection frac-
tion >40% were included. All patients consented in an
informed manner that samples might be use later in order
to investigate the involvement of new factors. After com-
pletion of the study, approximately 200 plasma samples
drawn before, during and after CABG were analysed for
various lipid mediators (platelet-activating factor, 6-keto
prostaglandin F1α, prostaglandin E2, thromboxane B2, leu-
kotriene B4 and C4), cytokines (interleukin 4, 6, 8, 10 and
13, tumor necrosis factor α, leukaemia inhibitory factor),
growth factors (macrophage-CSF, granulocyte-CSF, gran-
ulocyte-macrophage-CSF), and angiogenic factors (VEGF,
basic fibroblast growth factor, epidermal growth factor
and transforming growth factor β1). Manuscripts on the
involvement of these compounds during CABG have been
published separately [3-7]. At the time of the present
study, remaining plasma samples from 31 patients were
available for analysis of sFlt-1 levels. All plasma samples
were stored at -80°C until used. All samples undergo the
same number of freeze-thaw cycles (not more than 3). All
samples (from T0 to T5) were tested the same day.
All patients had a preoperative ejection fraction above
40%. Anaesthesia was induced and maintained with
titrated doses of fentanyl and flunitrazepam. Muscular
relaxation was achieved with pancuronium (0.1 mg/kg).
Membrane oxygenators were used. All patients received
300 U/kg of heparin just before vascular cannulation.
Incremental 100 U boluses of heparin were added each
hour during the procedure to maintain an activated clot-
ting time greater than 600 seconds. At the end of ECC pro-
tamine was administered in a 2:3 ratio with heparin. The
blood was harvested from the surgical field and from the
cell saver at the end of ECC and reinfused to all patients.
All patients received high doses of aprotinin and no
patients received corticoids. The following criteria were
used for weaning patients from ventilator. PaO2:FiO2 ratio
> 300, hemodynamic stability without vasoactive drugs,
complete rewarming of patients, no bleeding complica-
tions.
Plasma samples were collected from the radial artery cath-
eter before vascular cannulation and after opening the
chest (T0), at the end of ECC just before (T1) and after
cross clamp release (T2), after weaning from ECC (T3), at
the 6th (T4) and 24th post-operative hour (T5). The pres-
ence of complications was prospectively assessed. Cardio-
vascular dysfunction was determined at T3, T4 and T5
according to the need of inotropic drugs to obtain a systo-
lic arterial pressure (SAP) above 90 mm Hg. Myocardial
infarction and dysrhythmias were recorded. Pulmonary
artery occlusion pressure (PAOP), control veinus pressure
(CVP) and cardiac (and subsequent derived measures)
output were monitored by a swan ganz catheter. At the
time of the protocol systems monitoring blood volume by
analysis of arterial curve (such as Picco or Vigileo®) were
not available. Hematological complications were ensured
at T3, T4 and T5 by the presence of one of the following bio-
logical disorders: activated partial thromboplastin time
values > 1.5 greater than control, fibrinogen level < 1 g/L,
factor V level < 30%, platelet count < 70,000 elements/
mm3 or clinical bleeding (blood loss greater than 100 mL/
h). At T2 and T3, the Murray Lung Injury Score (without
measurements of compliances) was use to ensure the pres-
ence of respiratory complications [15].
Measurements of plasma sFlt-1 levels
Plasma sFlt-1 levels were measured with commercially
ELISA kits (R&D Systems, Abingdon, UK). Biological
results were expressed by pg/mg of protein measured at
the simultaneous times. The sensitivity of the assays ena-
bles the detection of levels as low as 20 pg/ml of sFlt-1.
The standard curve was linear, from 30 to 1000 pg/ml,
and plasma samples above this range was diluted by 1/10.
Results are expressed as mean ± SEM. The proteinemia
was determined by the BCA Protein Assay Reagent (Pierce,
Rockford, IL). No significant differences were found forPage 2 of 6
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shown).
Statistical analyses
Statistical analysis was performed by using analysis of var-
iance (ANOVA) for repeated measures (including the time
and the type of complication as covariables). Results were
considered statistically significant when P < 0.05.
Results and discussion
Among the 31 investigated patients, 15 had uneventful
surgery and 16 exhibited adverse outcomes. All these
adverse outcomes were summarized in Table 1. Four
patients had transient vital complications (including 1
with no evident sign of cardiovascular, haematological
and respiratory impairments; 1 with cardiovascular
impairments; 1 with cardiovascular and respiratory
impairments; 1 with cardiovascular, haematological and
respiratory impairments). These 4 patients were weaned
from the ventilator at the 24th post-operative hour. Twelve
patients had persistent vital complications (3 with respira-
tory impairments, 3 with cardiovascular and respiratory
impairments; 1 with cardiovascular and haematological
impairments; 3 with hematological and respiratory
impairments; 2 with cardiovascular, respiratory and
hematological impairments). Among them, three died
postoperatively at day 3, 6 and 14, respectively. No signif-
icant difference could be documented between the two
groups on several parameters including age, gender ratio,
weight, body surface area, ejection fraction, preoperative
left ventricular end diastolic pressure, number of grafts,
ECC duration, heparin total dose, protamine total dose,
preoperative blood infusion and blood reinfused by the
cell saver (data not shown).
A decrease of serum/plasma protein contents was
observed during and after CABG surgery [16]. To avoid
the influence of haemodilution during bypass, sFlt-1 lev-
els were expressed as ng/mg of total protein contents
measured at the simultaneous times. Plasma sFlt-1 values
of patients before CABG are shown in Figure 1. The mean
sFlt-1 plasma concentration was 5.9 pg/mg protein (range
0.6–35.0) in the uneventful group and 11.5 (range
0.7–61.0) in the complicated group. This difference was
not statistically significant (p = 0.41, Mann-Whitney U-
test). Raw data of patients (without proteinemia correc-
tion) were 301.6 pg/ml (range 30–1680) in the unevent-
ful group and 475.0 pg/ml (range 30–2660) in the
complicated group. Thus, pre-operative plasma sFlt-1
could not be used as a prognostic marker of post-operative
complication after CABG surgery. The values plasma con-
centrations reported here are similar like from those
detected in plasma from serum volunteers [17], showing
that long freezing and freeze-thaw cycles had any effect on
sFlt-1 levels. Moreover since similar pre-operative plasma
VEGF levels were found in these patients [7] abnormal
indices of angiogenesis were not evident between our two
groups of patients.
When sFlt-1 was evaluated during the course of CABG sur-
gery significant differences were found between compli-
cated and uneventful patients. Thus, lower circulating sFlt-
1 levels were observed in patients with hematological (p =
0.001, ANOVA test) and cardiovascular (p = 0.006)
impairments (Figure 2A and 2B, respectively). In contrast
sFlt-1 values were not significantly (p = 0.053) different in
patients with respiratory impairments as compared with
uneventful patients (Fig 2C). Finally lower sFlt-1 levels (p
= 0.013) were also evidenced for the 3 patients who died
postoperatively (Figure 2D). This study confirms in a set
of complicated patients the release of sFlt-1 during CABG
with ECC; sFlt-1 values of uneventful patients being previ-
ously reported separately [14]. In this study all patients
received aprotinin. The use of aprotinin in cardiac surgery
is currently the subject of much debate since aprotinin
might have modified the inflammatory response of our
patients [18]. However all patients (both uneventful and
complicated) received aprotinin. Thus, it is not the use of
aprotinin by itself that reduced sFlt-1 release in compli-
cated patients. In this study we investigated CABG surgery
with ECC. In the last few years, off-pump coronary artery
bypass grafting has gained widespread attention as an
alternative technique to conventional on-pump coronary
artery bypass grafting. However the available literature
Table 1: Type of impairments in complicated patients
Type of impairments Number of patients (n = 16)
Cardiovascular 1
Haematological 0
Respiratory 3
Cardiovascular and haematological 1
Cardovascular and respiratory 4
Haematological and respiratory 3
Cardiovascular, haematological and respiratory 3
No evident 1Page 3 of 6
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advantages of off-pump surgery with respect to the sys-
temic inflammatory response [19]. Moreover mortality,
stroke, myocardial infarction and renal failure were not
improved [20]. Clearly investigation of sFlt-1 and VEGF
release during off-pump cardiac surgery would be of inter-
est to ensure the involvement of angiogenic/anti-angionic
pathways during this type of cardiac surgery.
Data have demonstrated elevated VEGF levels following
CABG surgery [8,9], suggesting that VEGF is a component
of the inflammatory network after open heart surgery. In
a previous study we reported that plasma VEGF levels
were higher in patients with cardiovascular and hemato-
logical impairments as compared with patients with une-
ventful surgery [7]. The main finding of the present study
is that patients who developed cardiovascular or haema-
tological dysfunctions after CABG surgery had lower sFlt-
1 levels as compared with uncomplicated ones. Results
suggest that sFlt-1 production might play a protective role
in the occurrence of post-CABG complications. These
results are in agreement with data reporting decreased lev-
els of sFlt-1 and elevated levels of VEGF in patients with
coronary artery disease or myocardial infarction [21,22].
In culture sFlt-1 has been shown to block VEGF effects
[12,13]. Animal models have shown the interest of sFlt-1
infusion to improve cardiac function in a mouse model of
sepsis [23] and to reduce disease severity in experimental
inflammatory diseases [24,25].
Two possible mechanisms may be suggested to explain
the role of sFlt-1 in cardiac surgery. It is possible that sFlt-
1 might act by sequestering VEGF and, thus, preventing
signal transduction [12]. It is also possible that sFlt-1 can
act as an endogenous VEGF inhibitor by binding and inac-
tivating membrane-bound Flt-1 and KDR receptors [13].
We favour the second hypothesis since VEGF levels picked
at the 6th and 24th post-operative hours [7] while sFlt-1
levels picked during ECC. These kinetics of sFlt-1 and
VEGF release might indicate a similar sFlt-1 mechanism
for the diverse outcomes observed (cardiovascular and
haematological impairments).
Conclusion
Results of the current study strengthened the hypothesis
of a pathophysiological role for VEGF in mediating post-
Plasma sFlt1 before cardiopulmonary bypass graft surgeryFigure 1
Plasma sFlt1 before cardiopulmonary bypass graft surgery. Plasma sFlt-1 values were investigated before surgery in 
uncomplicated (n = 15) and complicated (n = 16) patients. Values are expressed in pg per mg protein. Mann-Whitney U-test 
was used to compare groups.Page 4 of 6
(page number not for citation purposes)
Journal of Cardiothoracic Surgery 2008, 3:16 http://www.cardiothoracicsurgery.org/content/3/1/16operative complications and that VEGF neutralisation in
vivo appears beneficial to reduce the development of
these post-operative adverse effects. However the present
work is an observational study that cannot, as such, estab-
lish a link of causality between sFlt-1 levels and adverse
outcomes after CABG. Only a clinical study investigating
the influence of sFlt-1 infusion on post-operative adverse
effects after CABG might establish such a link.
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Comparison of plasma sFlt-1 levels for complicated and uncomplicated patients during the course of CABGFigure 2
Comparison of plasma sFlt-1 levels for complicated and uncomplicated patients during the course of CABG. 
Plasma sFlt-1 values are expressed in pg per mg protein. T0: before vascular cannulation and after opening the chest; T1: during 
extracorporeal circulation (ECC); T2: at the end of ECC before cross clamp release; T3: after cross clamp release; T4: the 6th 
post-operative hour; T5: the 24th post-operative hour. A: sFlt-1 levels in 15 uncomplicated patients (solid squares) and 7 
patients with hematological impairments (open squares). B: sFlt-1 levels in 15 uncomplicated patients (solid squares) and 9 
patients with cardiovascular impairments (open squares). C: sFlt-1 levels in 15 uncomplicated patients (solid squares) and 13 
patients with respiratory impairments (open squares). D: sFlt-1 levels in 15 uncomplicated patients (solid squares) and 3 
patients who died postoperatively (open squares). Results were expressed as means ± SD Statistical differences were made 
using ANOVA test.Page 5 of 6
(page number not for citation purposes)
Journal of Cardiothoracic Surgery 2008, 3:16 http://www.cardiothoracicsurgery.org/content/3/1/16Publish with BioMed Central   and  every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
References
1. Weigand MA, Hörner C, Bardenheuer HJ, Bouchon A: The sys-
temic inflammatory response syndrome.  Best Pract Res Clin
Anaesthesiol 2004, 18:455-475.
2. Paparella D, Brister SJ, Buchanan MR: Coagulation disorders of
cardiopulmonary bypass: a review.  Intensive Care Med 2004,
30(10):1873-1881.
3. Nathan N, Denizot Y, Cornu E, Jauberteau MO, Chauveau C, Feiss P:
Cytokine and lipid mediator blood concentrations after cor-
onary artery surgery.  Anesth Analg 1997, 85:1240-1246.
4. Denizot Y, Lorgeot V, Cornu E, Nathan N: Plasma leukaemia
inhibitory factor, interleukin 6 and soluble interleukin 6
receptor levels during cardiopulmonary bypass with extra-
corporeal circulation.  Cytokine 1998, 10:303-306.
5. Nathan N, Preux PM, Feiss P, Denizot Y: Plasma interleukin-4,
interleukin-10, and interleukin-13 concentrations and com-
plications after coronary artery bypass graft surgery.  J Cardi-
othorac Vasc Anesth 2000, 14:156-160.
6. Denizot Y, Karoutsos S, Nathan N: Differential alterations in
plasma colony-stimulating factor concentrations after coro-
nary artery bypass graft surgery with extracorporeal circula-
tion.  Cytokine 2001, 13:314-316.
7. Denizot Y, Guglielmi L, Cornu E, Nathan N: Alterations in plasma
angiogenic growth factor concentrations after coronary
artery bypass graft surgery: relationships with post-opera-
tive complications.  Cytokine 2003, 24:7-12.
8. Burton PBJ, Owen VJ, Hafizi S, Barton PJR, Carr-White G, Koh T, De
Souza A, Yacoub MH, Pepper JR: Vascular endothelial growth
factor release following coronary artery bypass surgery:
extracorporeal circulation versus "beating heart" surgery.
Eur Heart J 2000, 21:1708-1713.
9. Cotton JM, Mathur A, Hong Y, Brown AS, Martin JF, Erusalimsky JD:
Acute rise of circulating vascular endothelial growth factor-
A in patients with coronary artery disease following cardiot-
horacic surgery.  Eur Heart J 2002, 23:953-959.
10. Smith SK: Angiogenesis, vascular endothelial growth factor
and the endometrium.  Hum Reprod Update 1998, 4:509-519.
11. Norrby K: Mast cells and angiogenesis.  APMIS 2002,
110:355-371.
12. Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z: Vascular
endothelial growth factor (VEGF) and its receptors.  FASEB J
1999, 13:9-22.
13. Kendall RL, Wang G, Thomas KA: Identification of a natural sol-
uble form of the vascular endothelium growth factor recep-
tor, FLT-1, and its heterodimerisation with KDR.  Biochem
Biophys Res Commun 1996, 226:324-328.
14. Denizot Y, Leguyader A, Cornu E, Laskar M, Orsel I, Vincent C,
Nathan N: Release of soluble vascular endothelial growth fac-
tor receptor-1 (sFlt-1) during coronary artery bypass sur-
gery.  J Cardiothorac Surg 2007, 2:38.
15. Murray JF, Matthay Ma, Luce JM, Flick M: An expanded definition
of the acute respiratory distress syndrome.  Am Rev Respir Dis
1988, 138:720-723.
16. Roth-Isigkeit A, Borstel TV, Seyfarth M, Schmucker P: Perioperative
serum levels of tumor-necrosis-factor alpha (TNF-alpha), IL-
1 beta, IL-6 and soluble IL-2 receptor in patients undergoing
cardiac surgery with cardiopulmonary bypass without and
with correction for haemodilution.  Clin Exp Immunol 1999,
118:242-246.
17. Barleon B, Reusch P, Totzke F, Herzog C, Keck C, Martiny-Baron G,
Marmé D: Soluble VEGFR-1 secreted by endothelial cells and
monocytes is present in human serum and plasma from
healthy donors.  Angiogenesis 2001, 4:143-154.
18. Van der Linden PJ, Hardy JF, Daper A, Trenchant A, De Hert SG:
Cardiac surgery with cardiopulmonary bypass: does apro-
tinin affect outcome?  Br J Anaesth 2007, 99:646-652.
19. Börgermann J, Scheubel RJ, Simm A, Silber RE, Friedrich I: Inflamma-
tory response in on-versus off-pump myocardial revasculari-
zation: is ECC really the culprit?  Thorac Cardiovasc Surg 2007,
55:473-480.
20. Cheng DC, Bainbridge D, Martin JE, Novick RJ, evidence-based peri-
operative clinical outcomes research group: Does off-pump coro-
nary artery bypass reduce mortality, morbidity, and
resource utilization when compared with conventional cor-
onary artery bypass? A meta-analysis of randomized trials.
Anesthesiology 2005, 102:188-203.
21. Chung NAY, Lydakis C, Belgore F, Blann AD, Lip GYH: Angiogen-
esis in myocardial infarction. An acute or chronic process?
Eur Heart J 2002, 23:1604-1608.
22. Chung NA, Lydakis C, Belgore F, Li-Saw-Hee FL, Blann AD, Lip GYH:
Angiogenesis, thrombogenesis, endothelial dysfunction and
angiographic severity of coronary artery disease.  Heart 2003,
89:1411-1415.
23. Yano K, Liaw PC, Mullington JM, Shih SC, Okada H, Bodyak N, Kang
PM, Toltl L, Belikoff B, Buras J, Simms BT, Mizgerd JP, Carmeliet P,
Karumanchi SA, Aird WC: Vacular endothelial growth factor is
an important determinant of sepsis morbidity and mortality.
J Exp Med 2006, 203:1447-1458.
24. Hamade N, Kuwano K, Yamada M, Hagimoto N, Hiasa K, Egashira K,
Nakashima N, Maeyama T, Yoshimi M, Nakanishi Y: Anti-vascular
endothelial growth factor gene therapy attenuates lung
injury and fibrosis in mice.  J Immunol 2005, 175:1224-1231.
25. Miotla J, Maciewicz R, Kendrew J, Feldmann M, Paleolog E: Treat-
ment with soluble VEGF receptor reduces disease severity in
murine collagen-induced arthritis.  Lab Invest 2000,
80:1195-1205.Page 6 of 6
(page number not for citation purposes)
